June 2017 Cancer Immunotherapy
Welcome to the first Special Edition of CONQUER: the patient voice, which focuses on immunotherapies in cancer. With the recent explosion of new immunotherapies being approved by the FDA for the treatment of patients with cancer, and their promise for improvements in survival and reduced adverse events, every patient with cancer should become familiar with these new therapies and the hope they bring to patients, survivors, and their family members.
FDA Approvals, News & UpdatesImmunotherapyNewsworthy
This article includes immunotherapies approved through May 2017.
Cancer ResearchClinical TrialsImmunotherapy
According to the Cancer Research Institute, only 3% to 6% of eligible patients with cancer participate in clinical trials in the United States. Read the reasons why clinical trials are a great option to consider.
Catherine Poole breaks down the emerging immunotherapy options for Melanoma, not to be confused with the common skin cancers (basal-cell carcinoma and squamous-cell carcinoma) largely caused by exposure to UV rays.
By Wayne Kuznar
Immunotherapy is all the rage today, but like any other treatment, it comes with side effects. Learn how to recognize and manage some of the common side effects.
Immunotherapies expose cancer cells to the immune system so it can attack them. Read about why these drugs work so well in some patients but in others the immune system doesn’t respond to these very promising drugs.
Check out some of the most exciting immunotherapies that are giving hope to people fighting this disease, which is responsible for 1 in every 4 cancer-related deaths in the United States.
By Laura Morgan
Take a look at the 5 new promising immunotherapies approved by the FDA for bladder cancer after decades of no new treatment options for this type of cancer.
Results 1 - 10 of 10